May 14, 2013
Mitotech is proud to present new data at ARVO 2015. One of the two posters that Mitotech is presenting in Denver this year will outline the results of its recent Phase II clinical study in patients with moderate to severe Dry Eye Syndrome. The study was conducted by Ora Inc (Andover, MA) in 2014. It demonstrated the positive effect of Mitotech's drug SkQ1 on both signs and symptoms of dry eye and the poster will highlight some of the key findings. At the same time the second poster will present the positive results of an In Vitro experiment showing the anti-inflammatory effect of SkQ1 in conjunctival epithelial cells performed in close collaboration with Dr. Yi Wei at the Icahn School of Medicine at Mount Sinai.